hotspot -WSS

hotspot

author：hotspot 2025-09-03 09:23:49 - browse：2135

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Boeing's 1st astronaut flight bumped into next year, more repairs needed

WSS

340B reform proposal comes out of Senate working group

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Top private equity targets in 2023: cardiology, clinical trials, lasers

A single Democrat is willing to weaken Medicare negotiation power

Why CTE doesn’t keep Americans from enjoying the Super Bowl

A single Democrat is willing to weaken Medicare negotiation power

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

At least 12 people were injured in a blast at a port in northwest Turkey

Drug repurposing or repositioning? The language matters

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Peter Hotez and the public health issue of online harassment

At least 12 people were injured in a blast at a port in northwest Turkey

Sports medicine is finally prioritizing gender equality

Updated Covid vaccine has 54% effectiveness, new study suggests

After affirmative action ruling, medical educators look to 'holistic review'

Problems with a popular proposal to regulate AI in health care

hotspot

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Johnson & Johnson sued for allegedly overpaying for workers' drugs

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Why workplace violence is so common in health care

focus

explore

hotspot

hotspot